Atrial fibrillation is a heart disorder caused by an abnormality in the typical sequence of electrical impulses that changes the rate at which the heart beats and begins in the heart's upper chambers (atria). According to Marketstack, the Global Atrial Fibrillation Surgery Market is expected to grow considerably during the forecasted period. Factors such as the ageing population, lifestyle changes, and the surge in chronic illnesses such as obesity and diabetes are predicted to drive the Global Atrial Fibrillation Surgery Market in the forecasted period. Further, a rise in the prevalence of atrial fibrillation in the technological advancement and for catheter ablation as a cardiac arrhythmia therapy is expected to drive the Global Atrial Fibrillation Surgery Market in the forecasted period. Furthermore, the rising research and development procedures highlight advancements in the Atrial fibrillation market in the forecasted period. However, the high cost of processes and regulatory issues associated with these devices is expected to hinder the Atrial Fibrillation Surgery Market in the forecasted period.

The increment of the atrial fibrillation market is prompted by the rise in the prevalence of atrial fibrillation in the technical developments, the elderly population, and an option for catheter ablation for cardiac arrhythmia therapy. The ambulatory surgical centre segment is expected to grow due to enhanced healthcare infrastructure, availability of skilled labour, and affordability. The rising patient pool and growing geriatric population suffering from lifestyle diseases like heart failure and atherosclerosis are expected to propel the market. However, compared to conventional surgeries, the benefits of minimally invasive surgeries will ultimately lead to segment growth. Surgical procedures such as Catheter Ablation and Minimaze are minimally invasive. This reduces the time required for the surgery and limits the need for long observation time post-surgery. Usually, patients can be discharged on the same day or after overnight observation. This allows these procedures to be carried out in Surgical Centers without difficulty. Hospitals are the preferred settings for atrial fibrillation surgeries, as these have the required equipment and personnel to perform the procedure. Atrial fibrillation surgeries could also be performed in ambulatory surgery centres and other specialized facilities. In addition, owing to the increasing burden of obesity, there is an increase in the number of people suffering from atrial fibrillation. Hence, it is believed that an increased prevalence of obesity is contributing to the development of the market. Advances in catheterization technology, like robot-assisted catheterization for cardiac catheterization, have advanced the digital imaging system. This system helps enhance the detection and intervention of cardiac diseases, which assists physicians in performing coronary-related procedures in digital cath labs. These laboratories specialize in diagnostic services for outpatient procedures in hospitals, ASCs, and physician's clinics. The accessibility of a combination of cardiac catheterization for the ablation process and post-procedure recovery area in the same system can help decrease the overall associated expenses. Thus, the rising establishment or improvement of digital cath labs worldwide will surge the adoption of the cardiac ablation process in atrial fibrillation surgical procedures, driving the growth of the focused market during the forecast period.

The North American region is expected to dominate the atrial fibrillation market. This is majorly attributed to the rising patient pool in the area and the presence of key players. The United States within the North American region is expected to dominate the market growth. With key players in the country, technological advancements and favourable insurance policies augment the market studied in the United States. Catheter ablation is a technique utilized to treat irregular cardiac rhythms when medicines are ineffective. It is a low-risk, minimally invasive method for treating cardiac arrhythmias. The catheter ablation technology removes abnormal cardiac tissues that cause irregular heartbeats. In treating cardiac arrhythmias, catheter ablation has a 95.0 per cent success rate. The advances in technology are one of the critical propellers supporting the atrial fibrillation surgery market. The technology provides high-resolution imaging of the heart tissues. This permits surgeons to pinpoint the exact location of the arrhythmia, enhancing the procedure's effectiveness. Implementing these types of devices will help surgeons decrease human errors and improve the quality of treatment. Surgeons can also use laser, cryoablation, and cryo energy-based ablation instead of Radio Frequency-based ablation to treat individuals with arrhythmias. This will lead to the need and use of sophisticated and advanced technologies bused ablation catheters.

Such increasing demand will drive market growth in the forecast period. The rise in the number of patients suffering from arrhythmia or irregular heartbeat has increased the demand for cardiac monitors. The pharmacological treatment segment held the most significant revenue in the atrial fibrillation market due to the high demand for anticoagulants and antiarrhythmic drugs. Anticoagulant drugs are the most commonly prescribed medication for patients with atrial fibrillation. Anticoagulant drugs help prevent blood clots and reduce the risk of stroke, which is a common complication of atrial fibrillation. Non-pharmacological techniques are becoming increasingly popular for treating atrial fibrillation. They are considered the primary method for comprehensive arrhythmia management due to the limited antiarrhythmic and frequent proarrhythmic effects of drugs. The highly developed healthcare infrastructure and favourable reimbursement policies in the region are the other factors driving the segment's growth. The Asia-Pacific region is projected to grow the fastest owing to the increase in awareness, the surge in public healthcare spending, and rapid growth in the prevalence of lifestyle diseases like obesity, diabetes, and high blood pressure.

The market key players are Boston Scientific Corporation, Medtronic Plc, Biotronik, AtriCure Inc., and Cardiofocus Inc., among others.

In May 2022, Abbott reported positive results from the PERSIST-END study of its TactiCath Contact Force Ablation Catheter, Sensor Enabled (TactiCath SE) for persistent atrial fibrillation (AFib), the most common arrhythmia.

In April 2022, The Atrial Fibrillation Institute was established within the Queensland Cardiovascular Group (QCG) to provide a focused, specialist service for people with Atrial Fibrillation.

Global Atrial Fibrillation Surgery Market report provides deep insight into the Industrial market's current and future state across various regions. The study comprehensively analyses the Atrial Fibrillation Surgery Market by segmenting based on Product (Catheter Ablation and Surgical Ablation), End User (Hospitals, Ambulatory Surgical Centers, and Other End Users), and Geography (Asia-Pacific, North America, Europe, South America, and Middle East & Africa). The report examines the market drivers and restraints and the impact of COVID-19 on market growth in detail. The study covers emerging market trends, development, opportunities, and challenges in the industry. This report also covers extensively researched competitive landscape sections with prominent companies and profiles, including their market shares and projects.